Hikma announces successful resolution to US FDA warning letter at Eatontown facility

London, 2 April 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that we have received a close-out letter from the US Food and Drug Administration (“US FDA”) that lifts the warning letter received in February 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market. This communication follows the US FDA’s re-inspection of the facility in February 2014 to complete its evaluation of the corrective actions we have taken in response to the warning letter. This successfully resolves all issues raised by the US FDA in February 2012 and all subsequent communications.

Press Release Corporate 24 April 2014

Said Darwazah, Chief Executive Officer of Hikma commented:

“I am pleased to report that we have brought the Eatontown facility back into compliance with the US FDA. The investment we have made to complete the remediation work, upgrade our manufacturing processes and strengthen our operations, provides greater quality and support for our customers and we are committed to continuing to invest in the highest quality standards. We are gradually re-introducing products to the US market from the Eatontown facility, adding to the products we supply from our US FDA-approved facilities in Jordan and Saudi Arabia. We believe there are an increasing number of attractive market opportunities for our Generics business and we are investing in our pipeline of oral and other non-injectable product forms, whilst continuing to look for further product acquisition opportunities.”

We expect the Generics business to deliver revenue of around $170 million in 2014, with an adjusted operating margin of above 25%.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.